GlassScriptPhysician profile
Amy Belloli Conner
NPI 1558881276
$4,676.19
in general payments reported to CMS, 2019-2025
22 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.93 · 2020: $357 · 2021: $294 · 2022: $1,075 · 2023: $764 · 2024: $735 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,895 · Honoraria: $25.59 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,895.23 |
| Honoraria | $25.59 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $528.53 | 2023-2025 | |
| Abbvie INC. | $527.20 | 2022-2025 | Durysta |
| Bausch & Lomb Americas INC. | $513.21 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $466.91 | 2020-2025 | Idosetr, Istent Infinite, Kxl System (Not Refurbished) |
| Visionary Optics LLC | $425.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $319.01 | 2022-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $283.02 | 2024-2025 | Xdemvy |
| Rxsight INC | $282.43 | 2024-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Dompe US, INC. | $192.61 | 2022-2025 | Oxervate |
| Harrow Eye, LLC | $190.42 | 2024-2025 | Vevye, Triesence |
| Novartis Pharmaceuticals Corporation | $174.72 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $146.25 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $124.99 | 2021 | |
| Horizon Therapeutics Plc | $124.99 | 2022 | |
| Alcon Vision LLC | $108.58 | 2020-2023 | Hydrus Microstent, Eysuvis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $60.21 | 2020-2021 | |
| Ocular Therapeutix, INC. | $52.94 | 2023-2024 | Dextenza |
| Oyster Point Pharma, INC. | $50.84 | 2023-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $36.69 | 2020 | |
| Eyevance Pharmaceuticals LLC | $28.71 | 2020-2022 | |
| Amgen INC. | $22.89 | 2025 | Tepezza |
| Thea Pharma INC. | $16.04 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.